Related Experiment Video
Updated: Feb 12, 2026

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
Published on: June 20, 2018
Genotype-Phenotype Analysis in Pediatric Patients with Distal Renal Tubular Acidosis
Eujin Park1, Myung Hyun Cho1, Hye Sun Hyun1
1Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Republic of Korea.
Insights
Genetic mutations in SLC4A1 are the most common cause of distal renal tubular acidosis in Korean children, presenting with later onset and milder symptoms. Long-term monitoring for renal function, hearing, and growth is crucial for affected children.
Area of Science:
- Pediatric Nephrology
- Medical Genetics
- Rare Genetic Disorders
Background:
- Primary distal renal tubular acidosis (dRTA) is a rare pediatric genetic disorder.
- Causative mutations identified in SLC4A1, ATP6V1B1, and ATP6V0A4 genes.
- Understanding genetic prevalence and phenotypic variation is critical for diagnosis and management.
Purpose of the Study:
- To analyze the prevalence and phenotypic differences of genetic mutations in children diagnosed with dRTA.
- To identify the most common causative genes in the Korean pediatric population.
- To correlate genotype with clinical presentation and long-term outcomes.
Main Methods:
- Genetic testing was performed on 17 children diagnosed with dRTA.
- Analysis included mutations in the three known causative genes: SLC4A1, ATP6V1B1, and ATP6V0A4.
- Clinical data including age of onset, metabolic acidosis severity, and long-term complications were collected.
Main Results:
- Pathogenic mutations were identified in 88.2% of patients, with six novel mutations found.
- SLC4A1 mutations were most prevalent (58.8%), followed by ATP6V0A4 (17.6%) and ATP6V1B1 (11.8%).
- SLC4A1 mutations were associated with later onset and less severe acidosis; ATP6V1B1 mutations correlated with sensorineural hearing loss. Nephrocalcinosis occurred in all patients. No genotype-phenotype correlation was observed for long-term prognosis.
Conclusions:
- SLC4A1 mutations are the predominant cause of dRTA in Korean children.
- Patients with SLC4A1 mutations experience a later disease onset and milder initial presentation.
- Long-term surveillance for hearing, renal function, and growth is essential for managing pediatric dRTA patients.
Background/Aims:
Primary distal renal tubular acidosis (dRTA) in children is a rare genetic disorder, and three causative mutated genes have been identified: SLC4A1, ATP6V1B1, and ATP6V0A4. We analyzed the prevalence and phenotypic differences of genetic mutations in children with dRTA.
Methods:
A total of 17 children with dRTA were enrolled in the study. All patients underwent genetic testing for all three candidate genes.
Results:
Pathogenic mutations, including six novel mutations, were detected in 15 (88.2%) patients: dominant SLC4A1 mutations in ten (58.8%) patients, recessive ATP6V0A4 mutations in three (17.6%) patients, and recessive ATP6V1B1 mutations in two (11.8%) patients. Compared to other patients, patients with SLC4A1 mutations showed an older age of onset (3.7 ± 2.6 years) and less severe metabolic acidosis at initial presentation. All patients developed nephrocalcinosis, and sensorineural hearing loss was observed in two patients with ATP6V1B1 mutations. Three (17.6%) patients had decreased renal function (chronic kidney disease stage 2), and five (29.4%) patients had persistent growth retardation at the last follow-up. Long-term prognosis showed no genotype-phenotype correlation.
Conclusions:
SLC4A1 is the most common defective gene in Korean children with dRTA. Patients with SLC4A1 mutations show later onset and milder disease severity. Long-term follow-up of hearing ability, renal function, and growth is necessary for patients with dRTA.
Related Concept Videos
Renal Drug Excretion: Tubular Reabsorption
Renal Drug Excretion: Tubular Secretion
Drug Elimination by Renal Route: Tubular Secretion
Drug Elimination by Renal Route: Tubular Reabsorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution

